EUVIMEDEUVIMED entdecken
Open Access

Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia

Ti-Cheng Chang iD, Wenan Chen iD, Chunxu Qu, Zhongshan Cheng, Dale Hedges, Abdelrahman Elsayed, Stanley B Pounds, Mary Shago, Karen R Rabin iD, Elizabeth A Raetz iD, Meenakshi Devidas iD, Cheng Cheng und 25 weitere

Journal of Clinical Oncology · 10.10.2024 · 42 (29) · 3491-3503

DOI: 10.1200/jco.23.02238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2024. Verfasst von Ti-Cheng Chang und 36 weiteren Autor:innen. Beteiligte Einrichtung: Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5 -altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10 –8 ). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10 –10 ; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10 –5 ; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1 , and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1 -like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHumansChildMaleFemaleCase-Control StudiesChild, PreschoolAdolescentGenomicsInfantPAX5 Transcription Factor

Substanzen

PAX5 Transcription FactorPAX5 protein, human

Autor:innen und Institutionen

  • Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN.
  • Division of Computational Biology, Mayo Clinic, Rochester, MN.
  • Department of Pathology, St Jude Children's Research Hospital, Memphis, TN.
  • Deceased.
  • Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Ti-Cheng Chang, Wenan Chen, Karen R Rabin, Elizabeth A Raetz, Meenakshi Devidas, Pradyuamna Baviskar, Michael J Burke, Andrew Carroll, Richard Harvey, Ilaria Iacobucci, Jeremy R Wang, Sima Jeha, Leonard Mattano, Kelly Maloney, Ching-Hon Pui, Nilsa C Ramirez, Cheryl Willman, Brent Wood, Stephen P Hunger, Charles G Mullighan, Mignon L Loh

Förderung

  • NCI NIH HHS

Zitieren

APA

Chang, T. C., Chen, W., Qu, C., Cheng, Z., Hedges, D., Elsayed, A., Pounds, S. B., Shago, M., Rabin, K. R., Raetz, E. A., Devidas, M., Cheng, C., Angiolillo, A., Baviskar, P., Borowitz, M., Burke, M. J., Carroll, A., Carroll, W. L., Chen, I. M., …, & Loh, M. L. (2024). Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 42(29), 3491-3503. https://doi.org/10.1200/jco.23.02238

Vancouver

Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2024;42(29):3491-3503. doi:10.1200/jco.23.02238

BibTeX
@article{Chang2024,
  author = {Chang, Ti-Cheng and Chen, Wenan and Qu, Chunxu and Cheng, Zhongshan and Hedges, Dale and Elsayed, Abdelrahman and Pounds, Stanley B and Shago, Mary and Rabin, Karen R and Raetz, Elizabeth A and Devidas, Meenakshi and Cheng, Cheng and Angiolillo, Anne and Baviskar, Pradyuamna and Borowitz, Michael and Burke, Michael J and Carroll, Andrew and Carroll, William L and Chen, I-Ming and Harvey, Richard and Heerema, Nyla and Iacobucci, Ilaria and Wang, Jeremy R and Jeha, Sima and Larsen, Eric and Mattano, Leonard and Maloney, Kelly and Pui, Ching-Hon and Ramirez, Nilsa C and Salzer, Wanda and Willman, Cheryl and Winick, Naomi and Wood, Brent and Hunger, Stephen P and Wu, Gang and Mullighan, Charles G and Loh, Mignon L},
  title = {Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {29},
  pages = {3491--3503},
  doi = {10.1200/jco.23.02238}
}
Kostenlos starten →